open access
Nivolumab for relapsed/refractory classical Hodgkin lymphoma after brentuximab vedotin failure – Polish Lymphoma Research Group real-life experience
Affiliations- Department of Hematology, Jagiellonian University, Kopernika 17, Krakow, Poland
- Department of Lymphoproliferative Diseases, Maria Sklodowska-Curie Centre of Oncology and Institute, Roentgena 5, Warsaw, Poland
- Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Szamarzewskiego 84, 60-569 Poznań, Poland
- Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw, Medical University, Pasteura 4, Wroclaw, Poland
- Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, Poland, Lublin, Poland
open access
Abstract
Aim
Polish centers analyzed retrospectively the real-life experience with nivolumab in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) patients, after brentuximab vedotin (BV ) failure.
Background
Despite the effective frontline treatment, for cHL patients relapsing after autologous stem cell transplantation, the only effective strategy remains the novel agents. Nivolumab, a checkpoint inhibitor, demonstrates the clinical benefit with an acceptable safety profile.
Materials and methods
Retrospective analysis included 16 adult patients with R/R cHL after BV failure. All patients received single-agent nivolumab 3 mg/kg every 2 weeks until disease progression or unacceptable toxicity.
Results
After six cycles of nivolumab the overall response rate was 81% (complete remission rate of 56%, partial remission rate of 25%). The median PFS was not reached after a median follow-up of 19 months. Adverse events (AEs) of any grade occurred in 12 patients (75%), including grade 3 AEs observed in 5 patients (31%). There were no AEs of grade 4 or 5. After a median of 25 nivolumab doses, 62% of responding patients proceeded to allogeneic stem cell transplantation.
Conclusion
Nivolumab monotherapy demonstrated a high efficacy and safety in R/R cHL patients after BV failure. More patients and longer follow-up may further establish the potential benefit.
Abstract
Aim
Polish centers analyzed retrospectively the real-life experience with nivolumab in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) patients, after brentuximab vedotin (BV ) failure.
Background
Despite the effective frontline treatment, for cHL patients relapsing after autologous stem cell transplantation, the only effective strategy remains the novel agents. Nivolumab, a checkpoint inhibitor, demonstrates the clinical benefit with an acceptable safety profile.
Materials and methods
Retrospective analysis included 16 adult patients with R/R cHL after BV failure. All patients received single-agent nivolumab 3 mg/kg every 2 weeks until disease progression or unacceptable toxicity.
Results
After six cycles of nivolumab the overall response rate was 81% (complete remission rate of 56%, partial remission rate of 25%). The median PFS was not reached after a median follow-up of 19 months. Adverse events (AEs) of any grade occurred in 12 patients (75%), including grade 3 AEs observed in 5 patients (31%). There were no AEs of grade 4 or 5. After a median of 25 nivolumab doses, 62% of responding patients proceeded to allogeneic stem cell transplantation.
Conclusion
Nivolumab monotherapy demonstrated a high efficacy and safety in R/R cHL patients after BV failure. More patients and longer follow-up may further establish the potential benefit.
Keywords
checkpoint inhibitor; Hodgkin Lymphoma; nivolumab, refractory; relapsed
About this articleTitle
Nivolumab for relapsed/refractory classical Hodgkin lymphoma after brentuximab vedotin failure – Polish Lymphoma Research Group real-life experience
Journal
Issue
Pages
228-233
Published online
2018-12-31
Page views
215
Article views/downloads
274
DOI
10.2478/ahp-2018-0026
Bibliographic record
Acta Haematol Pol 2018;49(4):228-233.
Keywords
checkpoint inhibitor
Hodgkin Lymphoma
nivolumab
refractory
relapsed
Authors
Monika Długosz-Danecka
Michał Szymczyk
Joanna Fischer
Anna Łojko-Dankowska
Justyna Rybka
Joanna Mańko
Katarzyna Duda
Wojciech Jurczak